Contact Us
Drug Search Results
More Filters [+]

Talampanel

Alternative Names: talampanel, ly300164
Latest Update: 2023-10-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: AMPA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Talampanel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Dyskinesias|Brain Stem Cancer|Glioma|Amyotrophic Lateral Sclerosis|Epilepsy|Glioblastoma|Movement Disorders|Parkinson's Disease|Oligodendroglioma|Astrocytoma|Hypertension|Conduct Disorder

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2008-002062-62

P2

Completed

Amyotrophic Lateral Sclerosis

2010-07-19

ALSTAR OL

P2

Terminated

Amyotrophic Lateral Sclerosis

2010-06-01

ALS

P2

Completed

Amyotrophic Lateral Sclerosis

2010-04-01

TAL-TQT-101

P1

Completed

Healthy Volunteers

2010-01-01

Recent News Events

Date

Type

Title

10/01/2023

PubMed

 AMPAR receptor inhibitors suppress proliferation of human small cell lung cancer cell lines.

06/01/2020

PubMed

 Molecular insights into the role of AMPA receptors in the synaptic plasticity, pathogenesis and treatment of epilepsy: therapeutic potentials of perampanel and antisense oligonucleotide (ASO) technology.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions